Saturday, May 10, 2025 5/10/2025

An artificial intelligence-driven distributed stereotactic radiosurgery strategy for multiple brain metastases management

Award Number: R01CA235723
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

An artificial intelligence-driven distributed stereotactic radiosurgery strategy for multiple brain metastases management - PROJECT SUMMARY Brain metastases (BMs) are a life-threatening neurological disease, but current treatment regimens cannot manage multiple (>4) BMs (mBMs) without causing strong adverse effects. Stereotactic radiosurgery (SRS), utilizing potent dose to irradiate BMs and quick dose falloff to spare nearby tissues, has proven to be an effective treatment regimen for limited-number and small-size BMs. However, SRS could not avoid high toxic dose when BMs are multiple, clustered, or adjacent to critical organs. To safe and effectively treat mBMs with SRS requires addressing these urgent needs: 1) to identify the maximum tolerable SRS dose; 2) to study neurocognitive decline and design strategies to preserve patients’ post-treatment quality of life; and 3) to develop and implement high-quality streamlined mBMs SRS treatment and follow-up care. To address mBMs SRS management needs, we aim to develop and implement an artificial intelligence (AI)- driven treatment planning system (TPS) and conduct a therapeutic intervention clinical trial, both dedicated to improve mBMs SRS treatment quality and efficiency. The AI-driven TPS, namely AimBMs, will have three AI- based computational modules, including AI-Segtor for automatic segmentation, AI-Predictor for treatment outcome prediction and AI-Planner for spatiotemporal distributed SRS plan optimization. AimBMs is initially developed based on retrospective data and facilitate the mBMs distributed SRS prospective phase I/II clinical trials, while the clinical trial will provide critical clinical knowledge and evidence as feedback to improve AimBMs performance. The ultimate goal of the project is to translate the AimBMs to routine clinical practice to improve mBMs SRS treatment quality, patients’ post-treatment QoL, and clinical facility workflow. In response to PAR-18-560, we have formed a multidisciplinary collaboration between radiation oncologists and medical physicists to develop a novel AI-driven distributed SRS technology and conduct a cancer-targeted therapeutic intervention for managing mBMs. The project’s innovations include: 1) novel SRS treatment planning technological capability enabled by AI-based auto-segmentation, treatment outcome prediction, and spatiotemporal plan optimization; 2) novel AI learning capability to improve developed AI tools’ performance through the coherent clinical trial. The technology development will support the therapeutic intervention clinical trial, while the clinical trial is designated to improve the developed system performance. This seamlessly integrated development mode ensures the developed system is clinically practical. Upon completion, our newly developed AimBMs will lay a solid foundation for mBMs SRS management and benefit a wide population of patients with BMs. Moreover, the AI-based treatment planning and treatment delivery infrastructure built for mBMs SRS can be transferred to other tumor sites to generate an even broader clinical impact.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $526,311 )
2024	2024	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	000	6	11/23/2023	NON-COMPETING CONTINUATION	$498,609
2024	2024	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	001	6	4/17/2024	NON-COMPETING CONTINUATION	$27,702
														Subtotal = $526,311

Issue Date FY: 2023 ( Subtotal = $538,756 )
2023	2023	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	001	5	3/15/2023	NON-COMPETING CONTINUATION	$43,980
2023	2023	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	000	5	12/6/2022	NON-COMPETING CONTINUATION	$494,776
														Subtotal = $538,756

Issue Date FY: 2022 ( Subtotal = $534,280 )
2022	2022	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	000	4	12/21/2021	NON-COMPETING CONTINUATION	$490,665
2022	2022	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	001	4	5/23/2022	NON-COMPETING CONTINUATION	$43,615
														Subtotal = $534,280

Issue Date FY: 2021 ( Subtotal = $118,985 )
2021	2021	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	000	3	2/12/2021	NON-COMPETING CONTINUATION	$118,985
														Subtotal = $118,985

Issue Date FY: 2020 ( Subtotal = $591,660 )
2020	2020	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	000	2	1/9/2020	NON-COMPETING CONTINUATION	$591,660
														Subtotal = $591,660

Issue Date FY: 2019 ( Subtotal = $599,533 )
2019	2019	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Treatment Research	000	1	12/20/2018	NEW	$599,533
														Subtotal = $599,533

Grand Total All Awards = $2,909,525

Top

All Categories

About

Search

Reports

Data Submission

Award Information

An artificial intelligence-driven distributed stereotactic radiosurgery strategy for multiple brain metastases management

Award Number: R01CA235723

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer